Search

Your search keyword '"Hand, Foot and Mouth Disease prevention & control"' showing total 250 results

Search Constraints

Start Over You searched for: Descriptor "Hand, Foot and Mouth Disease prevention & control" Remove constraint Descriptor: "Hand, Foot and Mouth Disease prevention & control"
250 results on '"Hand, Foot and Mouth Disease prevention & control"'

Search Results

1. Non-Polio Enterovirus Inhibitors: Scaffolds, Targets, and Potency─What's New?

2. Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study.

3. Influence of the Enterovirus 71 Vaccine and the COVID-19 Pandemic on Hand, Foot, and Mouth Disease in China Based on Counterfactual Models: Observational Study.

4. Impact of COVID-19 control measures on respiratory syncytial virus and hand-foot-and-mouth disease transmission in Hong Kong and South Korea.

5. Impact of non-pharmacological interventions on incidence of hand, foot and mouth disease during the COVID-19 pandemic: a large population-based observational study.

6. Trend of hand, foot and mouth disease before, during, and after China's COVID control policies in Zhejiang, China.

7. Rational design of a DNA-launched live attenuated vaccine against human enterovirus 71.

8. The effectiveness and impact of the enterovirus 71 vaccine on the onset of hand, foot, and mouth disease in children aged ≤5 years: A 7-year study.

9. Optimal control of bi-seasonal hand, foot and mouth disease in mainland China suggests transmission from children and isolating older infected individuals are critical.

10. Antiviral activity of povidone-iodine gargle and mouthwash solution against Enterovirus A71, Coxsackieviruses A16, A10 and A6.

11. Assessing the modification impact of vaccination on the relationship of the Discomfort Index with hand, foot, and mouth disease in Guizhou: A multicounty study.

12. Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.

13. Impact of the COVID-19 outbreak and interventions on hand, foot and mouth disease in Zhengzhou, China, 2014-2022: a retrospective study.

14. Quantitation of Enterovirus A71 Empty and Full Particles by Sedimentation Velocity Analytical Ultracentrifugation.

15. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.

16. Modeling and analysis of the effect of optimal virus control on the spread of HFMD.

17. Chinese parents' intention to vaccinate their 0-5-year-old children with the EV-71 vaccine against hand, foot, and mouth disease and willingness-to-pay.

18. Assessing the impact of COVID-19 interventions on the hand, foot and mouth disease in Guangdong Province, China: a Bayesian modeling study.

19. Immunogenicity of trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against EV-A71 and CV-A16.

20. Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally.

21. Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice.

22. Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism.

23. Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.

24. Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system.

25. [Analysis of the vaccination status of enterovirus type 71 inactivated vaccine in China from 2017 to 2021].

26. Hand, Foot, and Mouth Disease Outbreak What You Need to Know.

27. Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines.

28. Effects of different levels of non-pharmaceutical interventions on hand, foot and mouth disease in Guangzhou, China.

29. Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.

30. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017-2022: a descriptive study.

31. Effect of difference between EV-A71 virus epidemic strain and "vaccine strain" on neutralizing antibody titer.

32. The transfer of maternal antibodies and dynamics of maternal and natural infection-induced antibodies against coxsackievirus A16 in Chinese children 0-13 years of age: a longitudinal cohort study.

33. Insight into the Enterovirus A71: A review.

34. [Epidemiological Characteristics of Hand, Foot, and Mouth Disease and the Effect of EV71 Vaccination in Chengdu from 2012 to 2020].

35. Genetic and Cross Neutralization Analyses of Coxsackievirus A16 Circulating in Taiwan from 1998 to 2021 Suggest Dominant Genotype B1 can Serve as Vaccine Candidate.

36. The knowledge, attitudes and practices of hand, foot, and mouth disease prevention strategies amongst parents and educators of children under 5 years amidst COVID-19 pandemic: A cross-sectional study.

37. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV‑A71 vaccination in Kunming, China, 2017-2020.

38. The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: A longitudinal surveillance study.

39. Trend of hand, foot, and mouth disease from 2010 to 2021 and estimation of the reduction in enterovirus 71 infection after vaccine use in Zhejiang Province, China.

40. Effect of enterovirus 71 vaccination on the epidemiological characteristics and etiology in hospitalized children with hand-foot-and-mouth disease: A retrospective study from a tertiary children's hospital.

41. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD).

42. Hand-foot-and-mouth disease (HFMD) in children. Current scenario, and advancements in developing vaccines and therapeutics: An update - Correspondence.

43. Efficacy of Coxsackievirus A2 vaccine candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain.

44. Spatial-temporal-demographic and virological changes of hand, foot and mouth disease incidence after vaccination in a vulnerable region of China.

45. The impact of anti-COVID-19 nonpharmaceutical interventions on hand, foot, and mouth disease-A spatiotemporal perspective in Xi'an, northwestern China.

46. Does enterovirus 71 urge for effective vaccine control strategies? Challenges and current opinion.

47. Development of an Enzyme-Linked Immunosorbent Assay for Detection of the Native Conformation of Enterovirus A71.

48. A Novel Early Warning Model for Hand, Foot and Mouth Disease Prediction Based on a Graph Convolutional Network.

49. Impact of non-pharmaceutical interventions during COVID-19 pandemic on pertussis, scarlet fever and hand-foot-mouth disease in China.

50. A novel polypeptide vaccine and adjuvant formulation of EV71.

Catalog

Books, media, physical & digital resources